Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid syndrome in SLE

M C Amigo1, M A Khamashta, G R Hughes

  • 1Universidad Nacional Autónoma de México, Department of Rheumatology, Instituto Nacional de Cardiología lgnacio Chávez, Mexico Distrito Federal, Mexico.

Bailliere'S Clinical Rheumatology
|January 16, 1999
PubMed
Summary

Antiphospholipid syndrome (APS) affects 20-35% of patients with systemic lupus erythematosus (SLE), indicating a worse prognosis. Treatment involves anticoagulation for thrombotic events and aspirin/heparin for pregnancy loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does SLE flare during pregnancy?

Scandinavian journal of rheumatology. Supplement·1998
Same author

Therapeutic advances in systemic lupus erythematosus.

Current opinion in rheumatology·1998
Same author

Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein.

British journal of rheumatology·1998
Same author

Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome.

British journal of rheumatology·1998
Same author

Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.

Arthritis and rheumatism·1998
Same author

IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al.

Arthritis and rheumatism·1998

Area of Science:

  • Rheumatology
  • Immunology
  • Hematology

Background:

  • Antiphospholipid syndrome (APS) is frequently observed in patients with systemic lupus erythematosus (SLE).
  • Clinical manifestations of APS can occur before, during, or after SLE diagnosis.
  • Primary and secondary APS (associated with SLE) show similar clinical characteristics.

Purpose of the Study:

  • To review the association between APS and SLE.
  • To discuss the prognostic implications of concurrent APS in SLE patients.
  • To outline current and emerging treatment strategies for APS in SLE.

Main Methods:

  • Literature review of studies on antiphospholipid syndrome and systemic lupus erythematosus.
  • Analysis of clinical manifestations, diagnostic criteria, and treatment outcomes.

Related Experiment Videos

  • Synthesis of evidence regarding prognosis and therapeutic interventions.

    • Main Results:

    • APS occurs in 20-35% of SLE patients, often associated with a poorer prognosis.
    • Oral anticoagulation (INR close to 3) is recommended for preventing thrombotic events.
    • Aspirin, or aspirin with heparin, is used for recurrent fetal loss.

    Conclusions:

    • Concurrent APS in SLE patients signifies a worse clinical outcome.
    • Effective management strategies are crucial for improving prognosis in these patients.
    • Ongoing research aims to optimize treatments for cerebral ischemia and recurrent pregnancy loss in APS-SLE.